Cargando…

Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study

PURPOSE: Cognitive symptoms are reported to affect cancer survivors’ functioning at work. However, little is known about the type of cancer treatment and cognitive symptoms in working cancer survivors. We examined the longitudinal association between type of cancer treatment and cognitive symptoms i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehrenstein, Johanna K., van Zon, Sander K.R., Duijts, Saskia F.A., van Dijk, Boukje A.C., Dorland, Heleen F., Schagen, Sanne B., Bültmann, Ute
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182617/
https://www.ncbi.nlm.nih.gov/pubmed/31940106
http://dx.doi.org/10.1007/s11764-019-00839-w
_version_ 1783526264989024256
author Ehrenstein, Johanna K.
van Zon, Sander K.R.
Duijts, Saskia F.A.
van Dijk, Boukje A.C.
Dorland, Heleen F.
Schagen, Sanne B.
Bültmann, Ute
author_facet Ehrenstein, Johanna K.
van Zon, Sander K.R.
Duijts, Saskia F.A.
van Dijk, Boukje A.C.
Dorland, Heleen F.
Schagen, Sanne B.
Bültmann, Ute
author_sort Ehrenstein, Johanna K.
collection PubMed
description PURPOSE: Cognitive symptoms are reported to affect cancer survivors’ functioning at work. However, little is known about the type of cancer treatment and cognitive symptoms in working cancer survivors. We examined the longitudinal association between type of cancer treatment and cognitive symptoms in cancer survivors post return to work, and whether the course of cognitive symptoms over 18 months differed per type of cancer treatment. METHODS: Data from the Dutch longitudinal “Work-Life after Cancer” study were used. The study population consisted of 330 working cancer survivors who completed questionnaires at baseline, and 6, 12, and 18 months follow-up. Cognitive symptoms were assessed with the cognitive symptom checklist-work and linked with cancer treatment data from the Netherlands Cancer Registry. Data were analyzed using generalized estimating equations. RESULTS: Cancer survivors who received chemotherapy reported comparable memory symptom levels (b: − 2.3; 95% CI = − 7.1, 2.5) to those receiving locoregional treatment. Executive function symptom levels (b: − 4.1; 95% CI = − 7.8, − 0.4) were significantly lower for cancer survivors who received chemotherapy, compared with those receiving locoregional treatment. In cancer survivors who received other systemic therapy, memory (b: 0.4; 95% CI = 0.1, 0.7) and executive function symptom levels (b: 0.4; 95% CI = 0.0, 0.7) increased over time. In cancer survivors who received chemotherapy and locoregional treatment, memory and executive function symptom scores were persistent during the first 18 months after return to work. CONCLUSIONS: The contradictory finding that cancer patients receiving chemotherapy report fewer cognitive symptoms warrants further research. IMPLICATIONS FOR CANCER SURVIVORS: Working cancer survivors may have cognitive symptom management needs irrespective of the type of cancer treatment they received. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11764-019-00839-w) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7182617
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-71826172020-04-29 Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study Ehrenstein, Johanna K. van Zon, Sander K.R. Duijts, Saskia F.A. van Dijk, Boukje A.C. Dorland, Heleen F. Schagen, Sanne B. Bültmann, Ute J Cancer Surviv Article PURPOSE: Cognitive symptoms are reported to affect cancer survivors’ functioning at work. However, little is known about the type of cancer treatment and cognitive symptoms in working cancer survivors. We examined the longitudinal association between type of cancer treatment and cognitive symptoms in cancer survivors post return to work, and whether the course of cognitive symptoms over 18 months differed per type of cancer treatment. METHODS: Data from the Dutch longitudinal “Work-Life after Cancer” study were used. The study population consisted of 330 working cancer survivors who completed questionnaires at baseline, and 6, 12, and 18 months follow-up. Cognitive symptoms were assessed with the cognitive symptom checklist-work and linked with cancer treatment data from the Netherlands Cancer Registry. Data were analyzed using generalized estimating equations. RESULTS: Cancer survivors who received chemotherapy reported comparable memory symptom levels (b: − 2.3; 95% CI = − 7.1, 2.5) to those receiving locoregional treatment. Executive function symptom levels (b: − 4.1; 95% CI = − 7.8, − 0.4) were significantly lower for cancer survivors who received chemotherapy, compared with those receiving locoregional treatment. In cancer survivors who received other systemic therapy, memory (b: 0.4; 95% CI = 0.1, 0.7) and executive function symptom levels (b: 0.4; 95% CI = 0.0, 0.7) increased over time. In cancer survivors who received chemotherapy and locoregional treatment, memory and executive function symptom scores were persistent during the first 18 months after return to work. CONCLUSIONS: The contradictory finding that cancer patients receiving chemotherapy report fewer cognitive symptoms warrants further research. IMPLICATIONS FOR CANCER SURVIVORS: Working cancer survivors may have cognitive symptom management needs irrespective of the type of cancer treatment they received. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11764-019-00839-w) contains supplementary material, which is available to authorized users. Springer US 2020-01-15 2020 /pmc/articles/PMC7182617/ /pubmed/31940106 http://dx.doi.org/10.1007/s11764-019-00839-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Ehrenstein, Johanna K.
van Zon, Sander K.R.
Duijts, Saskia F.A.
van Dijk, Boukje A.C.
Dorland, Heleen F.
Schagen, Sanne B.
Bültmann, Ute
Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study
title Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study
title_full Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study
title_fullStr Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study
title_full_unstemmed Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study
title_short Type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study
title_sort type of cancer treatment and cognitive symptoms in working cancer survivors: an 18-month follow-up study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182617/
https://www.ncbi.nlm.nih.gov/pubmed/31940106
http://dx.doi.org/10.1007/s11764-019-00839-w
work_keys_str_mv AT ehrensteinjohannak typeofcancertreatmentandcognitivesymptomsinworkingcancersurvivorsan18monthfollowupstudy
AT vanzonsanderkr typeofcancertreatmentandcognitivesymptomsinworkingcancersurvivorsan18monthfollowupstudy
AT duijtssaskiafa typeofcancertreatmentandcognitivesymptomsinworkingcancersurvivorsan18monthfollowupstudy
AT vandijkboukjeac typeofcancertreatmentandcognitivesymptomsinworkingcancersurvivorsan18monthfollowupstudy
AT dorlandheleenf typeofcancertreatmentandcognitivesymptomsinworkingcancersurvivorsan18monthfollowupstudy
AT schagensanneb typeofcancertreatmentandcognitivesymptomsinworkingcancersurvivorsan18monthfollowupstudy
AT bultmannute typeofcancertreatmentandcognitivesymptomsinworkingcancersurvivorsan18monthfollowupstudy